Immunocore
IMCR
66 hedge funds and large institutions have $770M invested in Immunocore in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 5 closing their positions.
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
30% more capital invested
Capital invested by funds: $590M → $770M (+$179M)
16% more funds holding
Funds holding: 57 → 66 (+9)
2.96% more ownership
Funds ownership: 45.01% → 47.97% (+3%)
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
59% less call options, than puts
Call options by funds: $2.87M | Put options by funds: $7.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$69.4M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$5.46M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.89M |
| 4 |
AC
Armistice Capital
New York
|
+$2.86M |
| 5 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.2M |
| 2 |
SC
Samlyn Capital
New York
|
-$11.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.68M |
| 4 |
AG
Artal Group
Luxembourg
|
-$5.98M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
-$3.68M |
IMCR Hedge Fund Activity: Q2 2022 in Review
66 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q2 2022, worth a combined $770M — up 30% from $590M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IMCR positions and 5 closed out — a net gain of 9 holders — while 15 added to existing stakes and 18 trimmed.
The largest buyer was RTW Investments, adding an estimated $69.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $12.2M sold.
- 66 institutional investors held Immunocore (IMCR) as of Q2 2022, up from 57 in Q1 2022.
- Funds reported $770M of Immunocore stock for Q2 2022, up 30% quarter-over-quarter.
- 14 funds opened new Immunocore positions in Q2 2022 and 5 closed out, a net change of +9 holders.
- The largest Immunocore buyer in Q2 2022 was RTW Investments, an estimated $69.4M added.
- The largest Immunocore seller in Q2 2022 was Point72 Asset Management, an estimated $12.2M sold.
Based on aggregated 13F filings for Q2 2022.